Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial

Brian I. Rini, Michael B. Atkins, Elizabeth R. Plimack, Denis Soulières, Raymond S. McDermott, Jens Bedke, Sophie Tartas, Boris Alekseev, Bohuslav Melichar, Yaroslav Shparyk, Chihiro Kondoh, Przemyslaw Langiewicz, Lori A. Wood, Hans Hammers, Cynthia G. Silber, Barbara Haber, Erin Jensen, Mei Chen, Thomas Powles

Internal Medicine
Hematology & Oncology

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Sort by
Weight
Alphabetically

Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial

Fingerprint

Medicine & Life Sciences